Woulgan® Trademark Registered in Main Jurisdictions
Biotec Pharmacon’s Product Woulgan® Is Now Protected By Trademarks In Major Countries And Regions
TROMSØ, NORWAY, August 28, 2012 – Biotec Pharmacon ASA (OSE: BIOTEC) announced today the positive registration of trademark applications for Woulgan®by several international patent and trademark offices.
As a further milestone in the development of the Woulgan® concept, Biotec Pharmacon is proud to announce the registration of trademarks for Woulgan® in Europe (CTM), China Russia, Norway, Australia, Croatia and Iceland. Several international trademark applications are still pending in other jurisdictions.
"Given the vital importance of trademarks in the medical sector, we are very excited about these latest registrations in so many major jurisdictions. These registrations are important assets to support the uniqueness of the product, further enabling us to secure historical and future investments in the Woulgan® brand. Based on these registrations, we are also confident to obtain approval on remaining trademark applications for Woulgan® in other countries”, said Svein Lien, CEO, Biotec Pharmacon ASA.
For further information:
CEO Svein W. F. Lien: +47 92289323
CSO Rolf Engstad: +47 95941542
About Woulgan®:
Biotec BetaGlucans, a subsidiary of Biotec Pharmacon, has developed a novel biogel containing the Company's proprietary compound SBG® (Soluble Beta Glucan) for use in wound treatment. The finalized product, Woulgan® Biogel, offers the typical features of a medical device biogel formulation in addition to the biological wound healing enhancing ability of the SBG® component, considered to be an ancillary medicinal product in the formulation. Woulgan® Biogel is a sterile, homogenous, clear to hazy and viscous biogel containing Water, Glycerol, 2 % SBG®, and Carboxymethylcellulose. The product does not contain preservatives.
Mode of action:
Woulgan® Biogel provides a moist wound healing environment that promotes the natural healing process. Woulgan® Biogel contains a bioactive Soluble Beta Glucan.
Indications:
The Company has filed for registration of Woulgan® Biogel to be used as a primary dressing for dry or low exuding partial and full thickness dermal wounds within the following indications: diabetic ulcers, pressure ulcers, leg ulcers, graft and donor sites, postoperative surgical wounds (dermal lesions, trauma injuries or incisions), 1st and 2nd degree burns, abrasions and lacerations.
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The wholly owned Biotec BetaGlucans AS focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in wound treatment, cancer and gastroenterology. The company's technology is protected by a large patent portfolio covering amongst others applications of yeast beta-glucans as adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes AS aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.
More information at www.biotec.no.